132 related articles for article (PubMed ID: 30238171)
1. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; de Steur WO; Dikken JL; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Kranenbarg WMM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Gastric Cancer; 2019 Mar; 22(2):369-376. PubMed ID: 30238171
[TBL] [Abstract][Full Text] [Related]
2. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial.
Claassen YHM; de Steur WO; Hartgrink HH; Dikken JL; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Kranenbarg WMM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Ann Surg; 2018 Dec; 268(6):1008-1013. PubMed ID: 28817437
[TBL] [Abstract][Full Text] [Related]
3. Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial.
Claassen YHM; van Sandick JW; Hartgrink HH; Dikken JL; De Steur WO; van Grieken NCT; Boot H; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Br J Surg; 2018 May; 105(6):728-735. PubMed ID: 29652082
[TBL] [Abstract][Full Text] [Related]
4. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
6. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Eur J Surg Oncol; 2018 May; 44(5):613-619. PubMed ID: 29503129
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
Turanli S; Atalay C; Berberoglu U; Gulben K
J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
[TBL] [Abstract][Full Text] [Related]
8. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial.
de Steur WO; Hartgrink HH; Dikken JL; Putter H; van de Velde CJ
Br J Surg; 2015 Oct; 102(11):1388-93. PubMed ID: 26313463
[TBL] [Abstract][Full Text] [Related]
9. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
[TBL] [Abstract][Full Text] [Related]
11. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer.
Mrena J; Mattila A; Böhm J; Jantunen I; Kellokumpu I
World J Gastroenterol; 2015 Dec; 21(47):13294-301. PubMed ID: 26715812
[TBL] [Abstract][Full Text] [Related]
12. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.
de Steur WO; van Amelsfoort RM; Hartgrink HH; Putter H; Meershoek-Klein Kranenbarg E; van Grieken NCT; van Sandick JW; Claassen YHM; Braak JPBM; Jansen EPM; Sikorska K; van Tinteren H; Walraven I; Lind P; Nordsmark M; van Berge Henegouwen MI; van Laarhoven HWM; Cats A; Verheij M; van de Velde CJH;
Ann Oncol; 2021 Mar; 32(3):360-367. PubMed ID: 33227408
[TBL] [Abstract][Full Text] [Related]
14. Minimally invasive gastrectomy for gastric cancer: A national perspective on oncologic outcomes and overall survival.
Leung K; Sun Z; Nussbaum DP; Adam MA; Worni M; Blazer DG
Surg Oncol; 2017 Sep; 26(3):324-330. PubMed ID: 28807254
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
Shen J; Cao B; Wang Y; Xiao A; Qin J; Wu J; Yan Q; Hu Y; Yang C; Cao Z; Hu J; Yin P; Xie D; Gong J
Trials; 2018 Aug; 19(1):432. PubMed ID: 30092843
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.
Hundahl SA; Macdonald JS; Benedetti J; Fitzsimmons T;
Ann Surg Oncol; 2002 Apr; 9(3):278-86. PubMed ID: 11923135
[TBL] [Abstract][Full Text] [Related]
18. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
Kim S; Lim DH; Lee J; Kang WK; MacDonald JS; Park CH; Park SH; Lee SH; Kim K; Park JO; Kim WS; Jung CW; Park YS; Im YH; Sohn TS; Noh JH; Heo JS; Kim YI; Park CK; Park K
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1279-85. PubMed ID: 16099596
[TBL] [Abstract][Full Text] [Related]
19. The essentials of locoregional control in the treatment of gastric cancer.
den Dulk M; Verheij M; Cats A; Jansen EP; Hartgrink HH; Van de Velde CJ
Scand J Surg; 2006; 95(4):236-42. PubMed ID: 17249271
[TBL] [Abstract][Full Text] [Related]
20. Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results From the CRITICS Trial.
Claassen YHM; van Amelsfoort RM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Boot H; Trip AK; Jansen EPM; Kranenbarg EM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Ann Surg; 2019 Dec; 270(6):1096-1102. PubMed ID: 29995679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
